Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DV Biomed CoROCO:6539 66 Debt-to-EBITDA is 0.22 as of Jun. 2026, which is 5% above its 10-year median of 0.21. GuruFocus rates ROCO:6539 with a GF Score™ of 66/100 and a GF Value™ of NT$74.63 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 678 Drug Manufacturers companies, DV Biomed Co ranks better than 77.88% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for DV Biomed Co's Debt-to-EBITDA or its related term are showing as below:
ROCO:6539'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02 Med: 0.21 Max: 0.97
Current: 0.29
During the past 13 years, the highest Debt-to-EBITDA Ratio of DV Biomed Co was 0.97. The lowest was 0.02. And the median was 0.21.
ROCO:6539's Debt-to-EBITDA is ranked better than 77.88% of 678
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs ROCO:6539: 0.29
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
DV Biomed Co Debt-to-EBITDA Related Terms
DV Biomed Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for DV Biomed Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, DV Biomed Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DV Biomed Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DV Biomed Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where DV Biomed Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
DV Biomed Co (ROCO:6539) has a Debt-to-EBITDA of 0.22 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on DV Biomed Co. This is near median its historical median of 0.21. Over the past decade, DV Biomed Co's Debt-to-EBITDA has ranged from 0.02 to 0.97. According to the industry distribution chart, DV Biomed Co ranks #150 out of 678 companies in the Drug Manufacturers industry, placing it in the top 22.1%.
Is DV Biomed Co's Debt-to-EBITDA too high?
DV Biomed Co's current Debt-to-EBITDA of 0.22 is near median its 10-year median of 0.21. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.97. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. DV Biomed Co's value of 0.22 is 86.6% below this industry median. Based on the distribution chart, DV Biomed Co ranks #150 out of 678 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, DV Biomed Co has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does DV Biomed Co's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, DV Biomed Co ranks #150 out of 678 companies for Debt-to-EBITDA. This places DV Biomed Co in the top 22% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.64. DV Biomed Co's value of 0.22 is 86.6% below this benchmark. Historically, DV Biomed Co's own Debt-to-EBITDA has ranged from 0.02 to 0.97 over the past decade. While the company's 10-year median is 0.21 vs. the industry median of 1.64, DV Biomed Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 678 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DV Biomed Co's current Debt-to-EBITDA of 0.22 is 86.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on DV Biomed Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DV Biomed Co's current Debt-to-EBITDA is 0.22, which is near median its own 10-year median of 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DV Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, DV Biomed Co (ROCO:6539) is currently considered Possible Value Trap. The stock's GF Value™ is NT$74.63, compared to a current price of NT$40.90 — trading 45.2% below its estimated fair value. The current Debt-to-EBITDA is 0.22, which is near median its 10-year median of 0.21 and 86.6% below the Drug Manufacturers industry median of 1.64. DV Biomed Co's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For DV Biomed Co (ROCO:6539), the current Debt-to-EBITDA is 0.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DV Biomed Co (ROCO:6539) Overvalued in 2026?
Based on GuruFocus' analysis, DV Biomed Co stock appears to be undervalued.
The current stock price of NT$40.90 is trading 45.2% below its estimated GF Value™ of NT$74.63.
GuruFocus considers DV Biomed Co to be Possible Value Trap.
Key valuation signals for ROCO:6539:
Debt-to-EBITDA: 0.22 (near median its 10-year median of 0.21)
GF Value™: NT$74.63 vs. price of NT$40.90 (45.2% below fair value)
Industry Position: 86.6% below the Drug Manufacturers median (#150 of 678)
No single metric tells the full story. See the ROCO:6539 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DV Biomed Co Ltd provides medical supplies, skincare, and healthcare products. Its products include Perfectin and L'AMOUR Isis. The company also provides medical materials and needles (medicine), and healthcare products.
66GF Score
Get the complete analysis for ROCO:6539
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6539 has been successfully added to your 
